시장보고서

상품코드

1553581

POC(Point of Care) 감염증 검사 시장 규모, 점유율, 동향 분석 리포트 : 기술별, 질환별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Point Of Care Infectious Disease Testing Market Size, Share & Trends Analysis Report By Technology, By Disease (HIV POC, Clostridium Difficile POC), By End-use, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 08월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

POC(Point of Care) 감염증 검사 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 POC(Point of Care) 감염증 검사 시장 규모는 2030년까지 157억 6,000만 달러에 달하며, CAGR 4.3%를 기록할 것으로 예측됩니다.

환자 중심 서비스의 새로운 동향과 복잡한 감염성 질환의 발병률 증가로 인해 휴대용 및 정밀한 탐지 장비에 대한 수요가 급증하면서 시장 성장이 예상됩니다. 감염병을 신속하게 감지할 수 있는 이러한 기기의 잠재력이 시장 성장의 주요 요인으로 작용하고 있습니다.

또한 이러한 기기로 인한 환자 치료의 혁신은 분산형 검사 환경에 대한 수요 증가의 원인으로 작용하고 있습니다. 신제품 연구개발 및 시장 개척을 위한 투자 증가는 2025년까지 현장 진료 감염 진단 시장의 발전을 촉진할 것으로 예상됩니다.

예를 들어 EU의 프로젝트 연구팀이 개발한 새로운 "lab-on-a-disc" 기술은 말라리아를 포함한 다양한 감염병을 진단하는 데 도움이 될 수 있습니다. 현장 치료(point-of-care) 치료의 도입으로 보다 신속한 진단이 가능해졌습니다. 이를 통해 정확한 약물 투여가 가능해져 보급률에 영향을 미칠 수 있습니다.

POCT(Point-of-Care) 감염 검사 시장 보고서 하이라이트

COVID-19 부문은 2023년 67%의 점유율을 차지하며 시장을 장악했습니다. 이 높은 비율은 감염 환자 수 증가와 신속하고 쉽게 이용할 수 있는 진단 테스트 솔루션의 필요성에 기인합니다.
측면 유동 면역 분석은 예측 기간 중 가장 빠른 CAGR 5.7%를 나타낼 것으로 예상됩니다. 이러한 성장의 배경에는 호흡기 질환과 같은 감염성 질환의 유병률 증가와 현장 진단 장비의 기술 발전이 있습니다.
재택 부문은 예측 기간 중 CAGR 5.5%로 가장 빠르게 성장할 것으로 예상됩니다. 이는 노인들 사이에서 POC 테스트의 채택이 증가하고 개인화되고 예방적인 재택 요양 시설에 대한 중요성이 높아졌기 때문입니다.
아시아태평양은 정부의 적절한 지원으로 인해 감염증의 발병률과 유병률이 증가함에 따라 예측 기간 중 가장 빠른 성장세를 보일 것으로 예상됩니다.

부문 대시보드
POC(Point of Care) 감염증 검사 시장 : 질환별 변동 분석, 2023년 및 2030년
HIV POC
클로스트리듐 디피실 POC
HBV POC
폐렴 또는 연쇄구균 관련 감염증
호흡기세포융합바이러스(RSV) POC
HPV POC
인플루엔자/플루 POC
HCV POC
MRSA POC
결핵과 약제 내성 결핵 POC
HSV POC
COVID-19
기타 감염증

제6장 POC(Point of Care) 감염증 검사 시장 : 최종 용도별 추정·동향 분석

부문 대시보드
POC(Point of Care) 감염증 검사 시장 : 최종 용도별 변동 분석, 2023년 및 2030년
클리닉
병원
가정
요양시설
연구실

제7장 POC(Point of Care) 감염증 검사 시장 : 지역별 추정·동향 분석

POC(Point of Care) 감염증 검사 시장 점유율, 지역별, 2023년 및 2030년
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제8장 경쟁 구도

주요 시장 참여 기업에 의한 최근 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 개요
- Abbott
- Thermo Fisher Scientific Inc
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers
- Becton, Dickinson &Company
- Chembio Diagnostics Inc.
- Trinity Biotech
- Cardinal Health
- Quest Diagnostics Incorporated
- Bio-Rad Laboratories Inc.
- bioMerieux SA
- Sight Diagnostics Ltd.
- Gene POC
- Trivitron Healthcare
- OJ-Bio Ltd.
- Ortho-Clinical Diagnostics.

KSA 24.09.25

Point Of Care Infectious Disease Testing Market Growth & Trends:

The global point of care infectious disease testing market size is expected to reach USD 15.76 billion by 2030, registering a CAGR of 4.3%, according to a new report by Grand View Research, Inc. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.

Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in point-of-care infectious disease diagnostics market through to 2025.

For instance, development of a new 'lab-on-a-disc' technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.

Point Of Care Infectious Disease Testing Market Report Highlights:

COVID-19 segment dominated the market and accounted for a share of 67% in 2023. This high percentage can be attributed to the rising number of infectious cases and need for fast and accessible diagnostics testing solutions.
Lateral flow immunoassay is expected to register the fastest CAGR of 5.7% during the forecast period. The growth can be attributed to increasing prevalence of infectious diseases such as respiratory disease and technological advancements in point of care diagnostics device.
The home segment is projected to grow at the fastest CAGR of 5.5% over the forecast period, owing to increasing adoption of point of care testing among geriatric population and increasing emphasis on personalized and preventive home care facilities.
Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Point of Care Infectious Disease Testing Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Point of Care Infectious Disease Testing Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Point of Care Infectious Disease Testing Market: Technology Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Point of Care Infectious Disease Testing Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
4.3. Lateral Flow Immunoassay
- 4.3.1. Lateral Flow Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.4. Agglutination Test
- 4.4.1. Agglutination Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.5. Flow-through test/Immunoconcentration Assay
- 4.5.1. Flow-through test/Immunoconcentration Assay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.6. Molecular Diagnostics
- 4.6.1. Molecular Diagnostics Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.7. Others
- 4.7.1. Others Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Point of Care Infectious Disease Testing Market: Disease Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Point of Care Infectious Disease Testing Market: Disease Movement Analysis, 2023 & 2030 (USD Billion)
5.3. HIV POC
- 5.3.1. HIV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.4. Clostridium Difficile POC
- 5.4.1. Clostridium Difficile POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.5. HBV POC
- 5.5.1. HBV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6. Pneumonia or Streptococcus Associated Infections
- 5.6.1. Pneumonia or Streptococcus Associated Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.7. Respiratory Syncytial Virus (RSV) POC
- 5.7.1. Respiratory Syncytial Virus (RSV) POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8. HPV POC
- 5.8.1. HPV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9. Influenza/Flu POC
- 5.9.1. Influenza/Flu POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.10. HCV POC
- 5.10.1. HCV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.11. MRSA POC
- 5.11.1. MRSA POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.12. TB and Drug-resistant TB POC
- 5.12.1. TB and Drug-resistant TB POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.13. HSV POC
- 5.13.1. HSV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.14. COVID-19
- 5.14.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.15. Other Infectious Diseases
- 5.15.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Point of Care Infectious Disease Testing Market: End Use Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Point of Care Infectious Disease Testing Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
6.3. Clinics
- 6.3.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.4. Hospitals
- 6.4.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5. Home
- 6.5.1. Home Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6. Assisted Living Healthcare Facilities
- 6.6.1. Assisted Living Healthcare Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7. Laboratory
- 6.7.1. Laboratory Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Point of Care Infectious Disease Testing Market: Regional Estimates & Trend Analysis

7.1. Point of Care Infectious Disease Testing Market Share, By Region, 2023 & 2030 (USD Billion)
7.2. North America
- 7.2.1. North America Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.3. Canada
  - 7.2.3.1. Canada Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3. Europe
- 7.3.1. Europe Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.2. U.K.
  - 7.3.2.1. U.K. Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.3. Germany
  - 7.3.3.1. Germany Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.4. France
  - 7.3.4.1. France Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.5. Italy
  - 7.3.5.1. Italy Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.6. Spain
  - 7.3.6.1. Spain Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.9. Norway
  - 7.3.9.1. Norway Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.2. Japan
  - 7.4.2.1. Japan Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.3. China
  - 7.4.3.1. China Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.4. India
  - 7.4.4.1. India Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.5. Australia
  - 7.4.5.1. Australia Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Point of Care Infectious Disease Diagnostic Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Latin America
- 7.5.1. Latin America Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.4. UAE
  - 7.6.4.1. UAE Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. Abbott
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Thermo Fisher Scientific Inc
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. F. Hoffmann-La Roche Ltd
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Siemens Healthineers
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Becton, Dickinson & Company
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. Chembio Diagnostics Inc.
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Trinity Biotech
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Cardinal Health
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Quest Diagnostics Incorporated
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Bio-Rad Laboratories Inc.
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.11. bioMerieux SA
  - 8.4.11.1. Participant's Overview
  - 8.4.11.2. Financial Performance
  - 8.4.11.3. Product Benchmarking
  - 8.4.11.4. Recent Developments/ Strategic Initiatives
- 8.4.12. Sight Diagnostics Ltd.
  - 8.4.12.1. Participant's Overview
  - 8.4.12.2. Financial Performance
  - 8.4.12.3. Product Benchmarking
  - 8.4.12.4. Recent Developments/ Strategic Initiatives
- 8.4.13. Gene POC
  - 8.4.13.1. Participant's Overview
  - 8.4.13.2. Financial Performance
  - 8.4.13.3. Product Benchmarking
  - 8.4.13.4. Recent Developments/ Strategic Initiatives
- 8.4.14. Trivitron Healthcare
  - 8.4.14.1. Participant's Overview
  - 8.4.14.2. Financial Performance
  - 8.4.14.3. Product Benchmarking
  - 8.4.14.4. Recent Developments/ Strategic Initiatives
- 8.4.15. OJ-Bio Ltd.
  - 8.4.15.1. Participant's Overview
  - 8.4.15.2. Financial Performance
  - 8.4.15.3. Product Benchmarking
  - 8.4.15.4. Recent Developments/ Strategic Initiatives
- 8.4.16. Ortho-Clinical Diagnostics.
  - 8.4.16.1. Participant's Overview
  - 8.4.16.2. Financial Performance
  - 8.4.16.3. Product Benchmarking
  - 8.4.16.4. Recent Developments/ Strategic Initiatives